What is the appropriate diagnostic work‑up and treatment strategy for catamenial epilepsy in a menstruating woman of reproductive age who experiences seizure clustering around her menstrual cycle?

Diagnosis and Treatment of Catamenial Epilepsy

Diagnostic Approach

Catamenial epilepsy should be diagnosed through a systematic 4-step process involving menstrual and seizure charting for at least one cycle, with midluteal progesterone measurement to identify one of three distinct hormonal patterns. 1, 2

Step 1: Clinical History and Pattern Recognition

Document the following specific details:

• Menstrual cycle characteristics using a calendar chart for at least 6 months, noting cycle length and regularity 3, 1
• Seizure frequency and timing relative to menstrual phases, recording all seizure occurrences on the same calendar 2
• Associated symptoms including weight changes, hirsutism, galactorrhea, and menstrual irregularities (polymenorrhea <23 days, oligomenorrhea >35 days, amenorrhea >6 months) 3

Step 2: Hormonal Assessment

Obtain midluteal serum progesterone on day 22 of the menstrual cycle to distinguish ovulatory (>5 ng/mL) from anovulatory cycles, as this determines which catamenial pattern is present 2, 4

Additional hormonal workup if reproductive dysfunction is suspected:

• Testosterone and SHBG to evaluate for PCOS, particularly in women on valproate or with significant weight gain 3
• LH and FSH levels if menstrual irregularity or infertility is present 3
• Prolactin levels if galactorrhea or functional hyperprolactinemia is suspected 3

Step 3: Pattern Identification

Calculate average daily seizure frequency for each menstrual phase (divide cycle into: menstrual days -3 to +3, follicular days 4-9, ovulatory days 10 to -13, luteal days -12 to -4) 2

Three distinct catamenial patterns exist:

• C1 (Perimenstrual): Twofold or greater increase in seizure frequency during menstrual phase (days -3 to +3) in ovulatory cycles 2, 5
• C2 (Periovulatory): Twofold or greater increase at ovulation (days 10 to -13) in ovulatory cycles 2, 5
• C3 (Luteal): Twofold or greater increase throughout the second half of anovulatory cycles (inadequate luteal phase) 2, 5

A twofold or greater increase in average daily seizure frequency defines clinically significant catamenial epilepsy, affecting approximately one-third of women with epilepsy 2, 4

Step 4: Exclude Contributing Endocrine Disorders

Pelvic ultrasonography (transvaginal preferred) if PCOS is suspected based on clinical features or hormonal abnormalities 3

Pituitary MRI only if hyperprolactinemia or galactorrhea suggests hypothalamic-pituitary pathology 3

Common pitfall: Women with temporal lobe epilepsy have significantly higher rates of PCOS (10-25%), hypothalamic amenorrhea (12%), and premature ovarian failure (4%) compared to the general population, so maintain high clinical suspicion 3

---

Treatment Strategy

First-Line: Optimize Conventional Antiepileptic Drugs

The primary treatment approach is optimization of existing antiepileptic drug regimens, as there is no specific evidence-based treatment for catamenial epilepsy. 1, 6

Review and adjust current AED therapy to ensure it is appropriate for seizure type and not contributing to hormonal dysfunction 3

Critical consideration: Valproate causes menstrual irregularities in 45% of women and is associated with PCOS development, weight gain, and insulin resistance—consider switching to alternative AEDs if reproductive dysfunction is present 3

Enzyme-inducing AEDs (carbamazepine, phenobarbital, phenytoin) reduce biologically active sex hormone levels through increased SHBG production and may worsen hormonal imbalances 3

Second-Line: Intermittent Cyclic Treatments (for Regular Menses)

If conventional AED optimization fails, consider pattern-specific intermittent therapy during vulnerable days:

For C1 Pattern (Perimenstrual)

Natural progesterone 200 mg three times daily (600 mg/day total) from day 14-28 showed benefit specifically for perimenstrual exacerbations in the largest controlled trial, though overall evidence remains limited 5, 7, 6

Important caveat: The major RCT showed conflicting results—one demonstrated significant reduction in seizure frequency with progesterone, while another showed no difference from placebo 7, 6. The therapy was generally well-tolerated with no significant increase in withdrawals (RR 1.56,95% CI 0.81-3.00) 6

Alternative options for C1 pattern:

• Clobazam (benzodiazepine) used cyclically during perimenstrual days 8, 5
• Acetazolamide during vulnerable days 8, 5
• Increase existing AED dose temporarily during perimenstrual period 5

For C2 and C3 Patterns

Evidence is insufficient for specific treatments targeting ovulatory or luteal patterns 5, 6

Norethisterone showed no treatment difference compared to placebo in two small crossover RCTs (very low-certainty evidence) 6

Third-Line: Hormonal Cycle Suppression (for Irregular Menses or Treatment Failure)

For women with irregular menses or failed intermittent treatments, consider pharmacologic cessation of menstruation:

• Medroxyprogesterone acetate (Depo-Provera) for complete cycle suppression 5
• Continuous oral contraceptives (without placebo week) 5
• GnRH analogues (triptorelin, goserelin) in refractory cases 6

Major caveat: These approaches lack high-quality evidence and carry risks including bone health concerns, cardiovascular effects, and fertility implications that must be discussed 6

Multidisciplinary Management

Collaborate with endocrinology/gynecology when reproductive endocrine disorders are identified, as neurologists may lack detailed understanding of hormonal management in epilepsy 3

Monitor for long-term complications of reproductive dysfunction including infertility, increased migraine, emotional disorders, and female malignancies associated with PCOS 3

---

Key Clinical Pitfalls

• Do not rely on patient-reported catamenial patterns alone—prospective charting with progesterone measurement is essential, as self-reported patterns do not reliably predict documented patterns 4
• Single abnormal laboratory findings without symptoms may not require treatment, but warrant monitoring for development of symptomatic disorders 3
• Balance seizure control against hormonal side effects when changing AEDs—the cumulative side effects of alternative agents must be weighed carefully 3
• App-based tracking is useful for modern documentation of seizure and menstrual patterns 4